» Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008
New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the company’s once-daily, investigational non-nucleoside reverse…